Study identifier:D2550C00004
ClinicalTrials.gov identifier:NCT01937338
EudraCT identifier:N/A
CTIS identifier:N/A
A Double blind, Randomised, Placebo-controlled, 2-period, Cross-over Study in Healthy Volunteers to Investigate the Effects of a Single Dose of Inhaled AZD7624 on White Blood Cells and Inflammatory Markers in Induced Sputum and Blood after Oral Inhalation of 45,000 Endotoxin Units Lipopolysaccharide (LPS)
LPS Challenge, Neutrophils
Phase 1
Yes
AZD7624, Placebo
All
60
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2016 by AstraZeneca
AstraZeneca
-
Study to investigate the effect of a single dose of AZD7624 on inflammation caused by an endotoxin challenge.
This is a double-blind, randomised, placebo controlled, 2-way cross-over study to investigate the effects of a single dose of inhaled AZD7624 on white blood cells and inflammatory markers in induced sputum and blood after oral inhalation of LPS as well as the safety, tolerability and pharmacokinetics (PK) of AZD7624 following a single inhaled dose.
Location
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: AZD7624 | Drug: AZD7624 nebuliser solution; 20 mg/mL for inhalation |
Placebo Comparator: Placebo | Drug: Placebo nebuliser solution for inhalation |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.